This study describes point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out-of-pocket changes in spending as a result of decreasing coinsurance and price changes between 2010 and 2019.
No takes yet. Share an insight, caveat, or question.
Dusetzina et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: